Bronchitis– Pipeline Insight, 2020
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Bronchitis– Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Bronchitis: Overview
Bronchitis is a condition in which the airways in the lungs, called bronchial tubes, become inflamed and cause coughing, often with mucus. Bronchitis can be acute or chronic.
Symptoms
Signs and symptoms of both acute and chronic bronchitis include:
During the first few days of illness, it can be difficult to distinguish the signs and symptoms of bronchitis from those of a common cold.
Treatment of acute bronchitis is typically divided into two categories: antibiotic therapy and symptom management. Physicians appear to deviate from evidence-based medical practice in the treatment of bronchitis more than in the diagnosis of the condition.
Bronchitis Emerging Drugs Chapters
This segment of the Bronchitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bronchitis Emerging Drugs
Further product details are provided in the report……..
Bronchitis: Therapeutic Assessment
This segment of the report provides insights about the different Bronchitis drugs segregated based on following parameters that define the scope of the report, such as:
Bronchitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchitis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Bronchitis– Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Bronchitis: Overview
Bronchitis is a condition in which the airways in the lungs, called bronchial tubes, become inflamed and cause coughing, often with mucus. Bronchitis can be acute or chronic.
Symptoms
Signs and symptoms of both acute and chronic bronchitis include:
- a persistent cough, which may produce mucus
- wheezing
- a low fever and chills
- a feeling of tightness in the chest
- a sore throat
- body aches
- breathlessness
- headaches
- a blocked nose and sinuses
During the first few days of illness, it can be difficult to distinguish the signs and symptoms of bronchitis from those of a common cold.
- Chest X-ray. A chest X-ray can help determine if the patient have pneumonia or another condition that may explain your cough.
- Sputum tests. Sputum can also be tested for signs of allergies.
- Pulmonary function test.
Treatment of acute bronchitis is typically divided into two categories: antibiotic therapy and symptom management. Physicians appear to deviate from evidence-based medical practice in the treatment of bronchitis more than in the diagnosis of the condition.
Bronchitis Emerging Drugs Chapters
This segment of the Bronchitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bronchitis Emerging Drugs
- DW 1601: Daewon Pharmaceutical
Further product details are provided in the report……..
Bronchitis: Therapeutic Assessment
This segment of the report provides insights about the different Bronchitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Bronchitis
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Bronchitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchitis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Bronchitis R&D. The therapies under development are focused on novel approaches to treat/improve Bronchitis.
- Bronchitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Bronchitis drugs?
- How many Bronchitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bronchitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Zambon SpA
- Yuhan Corporation
- Theravance Biopharma
- Genentech, Inc.
- GlaxoSmithKline
- Novartis
- SolAeroMed Inc.
- Reata Pharmaceuticals, Inc.
- Pulmatrix
- Pharmaxis
- PharmaKing
- NovaBiotics.
- Merck Sharp & Dohme Corp.
- Johnson & Johnson Pharmaceutical Research & Development
- Ionis Pharmaceuticals, Inc.
- Incyte Corporation
- EmeraMed
- Daewon Pharmaceutical Co., Ltd.
- Chong Kun Dang Pharmaceutical
- Breath Therapeutics Inc.
- Boehringer Ingelheim
- BioMarck Pharmaceuticals
- Beyond Air
- AstraZeneca
- APT Pharmaceuticals, Inc.
- Abgenix
- Abbott
- N-acetylcysteine (NAC)
- YHD001
- V-306 candidate vaccine
- Tiotropium
- TD-4208
- Pirfenidone
- SB-240563 (Mepolizumab)
- AD 237
- S1226
- Bardoxolone methyl
- PUR003
- TPI 1020
- N02RS1
- Combination of Broussonetia spp and Lonicera spp
- QBW251
- Cysteamine
- MK-0476
- levofloxacin
- ION-827359
- Itacitinib
- GSK573719
- Emeramide
- DW1601
- CKD-497
- Liposomal Cyclosporine A
- BIBW 2948
- BIO-11006
- Nitric Oxide
- Aclidinium bromide
- Formoterol/Budesonide
- ABX-IL8
Introduction
Executive Summary
Bronchitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bronchitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bronchitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bronchitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DW 1601: Daewon Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Bronchitis Key Companies
Bronchitis Key Products
Bronchitis- Unmet Needs
Bronchitis- Market Drivers and Barriers
Bronchitis- Future Perspectives and Conclusion
Bronchitis Analyst Views
Bronchitis Key Companies
Appendix
Executive Summary
Bronchitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bronchitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bronchitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bronchitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DW 1601: Daewon Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Bronchitis Key Companies
Bronchitis Key Products
Bronchitis- Unmet Needs
Bronchitis- Market Drivers and Barriers
Bronchitis- Future Perspectives and Conclusion
Bronchitis Analyst Views
Bronchitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Bronchitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Bronchitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Bronchitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Bronchitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
